Pfizer Inc. struck a deal with Blackstone Inc. to secure as much as $1.5 billion in funding to develop one of its experimental obesity drugs, giving the company additional capital as it races to compete in the booming weight-loss market.
Under the agreement announced Wednesday, funds managed by Blackstone Life Sciences will cover up to $1.5 billion in development costs through 2028 for an obesity drug that Pfizer is testing as a monthly weight-loss injection. In exchange, Blackstone will be eligible for payments tied to US regulatory approval and certain sales milestones. Pfizer will retain full ownership and control of the medicine, according to a statement from the companies.
Pfizer is seeking to challenge market leaders Eli Lilly & Co. and Novo Nordisk A/S in the weight-loss market after acquiring Metsera Inc. for up to $10 billion last year. Pfizer plans to advance more than 20 clinical trials across its obesity portfolio this year, including 10 late-stage studies.
Pfizer Chief Financial Officer Cecile Guegan said in a statement the agreement would help the company pursue its expansive obesity program while preserving resources for other therapeutic areas.
Blackstone has been increasingly involved in funding drug development in recent years. In 2024, it reached an agreement to help fund trials of Moderna Inc.’s influenza shot, which was approved in the US this summer.
More stories like this are available on bloomberg.com
Published on November 12, 2026




